Provided by Tiger Fintech (Singapore) Pte. Ltd.

IGC Pharma

0.2940
-0.0060-2.00%
Post-market: 0.2876-0.0064-2.18%19:57 EDT
Volume:268.11K
Turnover:78.56K
Market Cap:23.43M
PE:-2.43
High:0.2987
Open:0.2965
Low:0.2870
Close:0.3000
Loading ...

IGC Pharma Adds Canadian Site to Phase 2 Trial of Investigational Alzheimer's Dementia Therapy

MT Newswires Live
·
20 Mar

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences

ACCESS Newswire
·
20 Mar

IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the "Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results"

ACCESS Newswire
·
10 Mar

IGC Pharma Price Target Maintained With a $3.50/Share by Alliance Global Partners

Dow Jones
·
07 Mar

IGC Pharma develops AI-driven model to improve diagnosis of Alzheimer’s

TIPRANKS
·
04 Mar

IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection

ACCESS Newswire
·
04 Mar

IGC Pharma Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
24 Feb

IGC Pharma expands Holiby line with ‘Longevity’, ‘Renew’

TipRanks
·
21 Feb

IGC Pharma Q3 Revenue USD 257 Thousand

THOMSON REUTERS
·
18 Feb

IGC Pharma Reports Third Quarter Fiscal 2025 Results

ACCESS Newswire
·
18 Feb

IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby(TM)

ACCESS Newswire
·
11 Feb

IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer's Disease

ACCESS Newswire
·
28 Jan

IGC Pharma Appoints Former Virginia Governor Terry McAuliffe as Strategic Advisor

ACCESS Newswire
·
21 Jan

UPDATE 1-IGC trims global corn crop forecast, US estimate cut

Reuters
·
16 Jan

IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets

ACCESSWIRE
·
13 Jan

IGC Pharma names IGC-AD1 Phase 2 clinical trial ‘CALMA’

TIPRANKS
·
08 Jan